Aripiprazole Tablet
Product Images NDC 29300-178

18 FDA label images from Unichem Pharmaceuticals (usa), Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 29300-178). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 01)

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 01)
Chemical structure of Aripiprazole, depicting its molecular components including two chlorine atoms and several interconnected ring structures, as well as the attached side chains.*
FDA Label Image

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (F1daa6df 15e5 4f75 B656 6f99906e98e0 02)

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (F1daa6df 15e5 4f75 B656 6f99906e98e0 02)
A pharmacokinetic chart illustrating the effect of various interacting drugs on Aripiprazole plasma levels. It shows fold change and 90% confidence intervals in AUC and Cmax for CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs compared to reference values without interacting drugs.*
FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 03)

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 03)
A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole,' showing fold changes and 90% confidence intervals in dehydro-aripiprazole levels relative to a reference without interacting drugs. The chart compares effects of CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) on AUC and Cmax parameters.*
FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 04)

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 04)
A chart showing the effect of Aripiprazole on the pharmacokinetics of other drugs, measuring fold change and 90% confidence intervals. The chart compares changes in parameters such as AUC and Cmax for drugs metabolized by enzymes CYP2D6, CYP2C9, 2C19, and UGT1A4, including dextrormethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis shows change relative to reference without interacting drug, ranging from 0.5 to 3.0.*
FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 05)

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 05)
A chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic (PK) comparisons for various special populations. It depicts fold changes in AUC and Cmax relative to reference for groups including CYP2D6 metabolizer status, gender, age, hepatic impairment, and severe renal impairment, with data points and 90% confidence intervals on a horizontal axis ranging approximately from 0.5 to 3.0.*
FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 06)

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 06)
A forest plot graph showing fold change and 90% confidence intervals for dehydro-aripiprazole exposure under various conditions compared to reference. Variables include CYP2D6 metabolizer status, gender, age groups, and degrees of hepatic and renal impairment, with changes measured for both AUC and Cmax relative to reference values.*
FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 07)

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 07)
A line graph comparing the proportion of subjects experiencing relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization (0 to 182), and the y-axis shows the proportion with relapse (0 to 1.0). Aripiprazole shows a lower relapse proportion than placebo. A table below the graph lists the number of subjects at risk at several time points for each group.*
FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 08)

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 08)
A line graph comparing the proportion of relapse over days from randomization between two groups: Aripiprazole and Placebo. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1.0. The graph includes numbers of subjects at risk for each group at various time points below the x-axis.*
FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 09)

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 09)
A Kaplan-Meier survival curve chart showing the proportion of subjects with relapse over days from randomization for Aripiprazole versus placebo groups. The x-axis represents days from randomization, and the y-axis represents the proportion with relapse. The graph includes the number of subjects at risk listed below the x-axis for both treatment groups.*
FDA Label Image

Figure9 (F1daa6df 15e5 4f75 B656 6f99906e98e0 10)

Figure9 (F1daa6df 15e5 4f75 B656 6f99906e98e0 10)
A line graph showing the change in YGTSS total TIC score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo. The Y-axis represents the least-squares mean change in YGTSS total TIC score, and the X-axis represents weeks of treatment from 0 to 8.*
FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 11)

FDA Label Image

Image (F1daa6df 15e5 4f75 B656 6f99906e98e0 899 2)

FDA Label Image

Aripiprazole Tablets, Usp 2 mg (30's count)

Aripiprazole Tablets, Usp 2 mg (30's count)
Label for Aripiprazole Tablets, USP 2 mg, showing a bottle containing 30 tablets. The label includes dosing instructions to see the package insert and storage conditions at 20° to 25°C. It is manufactured by Unichem Laboratories Ltd., India, and labeled by Unichem Pharmaceuticals (USA), Inc. The label also features a barcode and the NDC number 29300-175-13.*
FDA Label Image

Aripiprazole Tablets, Usp 5 mg (30's count)

Aripiprazole Tablets, Usp 5 mg (30's count)
Label for Aripiprazole Tablets, USP 5 mg oral tablets, packaged as 30 tablets. The label includes the NDC number 29300-176-13, manufacturer Unichem Laboratories Ltd. in India, and the labeler Unichem Pharmaceuticals (USA), Inc. Storage instructions specify 20° to 25°C, with warnings to keep out of reach of children.*
FDA Label Image

Aripiprazole Tablets, Usp 10 mg (30's count)

Aripiprazole Tablets, Usp 10 mg (30's count)
Aripiprazole 10 mg tablets label displaying the NDC 29300-177-13. It is a human prescription drug by Unichem Pharmaceuticals (USA), Inc. The label includes dosage strength, quantity of 30 tablets, storage instructions, manufacturer information, and barcode. The tablets are USP grade and for oral use.*
FDA Label Image

Aripiprazole Tablets, Usp 15 mg (30's count)

Aripiprazole Tablets, Usp 15 mg (30's count)
Label for Aripiprazole Tablets, USP 15 mg by Unichem Pharmaceuticals (USA), Inc. The label indicates each tablet contains 15 mg of Aripiprazole, with a quantity of 30 tablets. It includes storage instructions (20° to 25°C), a warning to keep out of reach of children, and prescription-only status. The label also shows the NDC number 29300-178-13 and manufacturer details: Unichem Laboratories Ltd., India, and Unichem Pharmaceuticals (USA), Inc., New Jersey.*
FDA Label Image

Aripiprazole Tablets, Usp 20 mg (30's count)

Aripiprazole Tablets, Usp 20 mg (30's count)
Label for Aripiprazole Tablets, USP containing 20 mg per tablet, in a package of 30 tablets. The label includes storage instructions, manufacturer information for Unichem Laboratories Ltd. and Unichem Pharmaceuticals (USA), Inc., and a barcode. The label emphasizes prescription-only status and advises keeping the drug out of reach of children.*
FDA Label Image

Aripiprazole Tablets, Usp 30 mg (30's count)

Aripiprazole Tablets, Usp 30 mg (30's count)
Label for Aripiprazole Tablets, USP, 30 mg strength, oral tablets. The label indicates a package of 30 tablets and includes storage instructions to keep at 20° to 25°C (68° to 77°F). It is manufactured by Unichem Laboratories Ltd. in India and labeled by Unichem Pharmaceuticals (USA), Inc. The label notes the prescription-only status and cautions to keep drugs out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.